2 active not recruiting, 2 completed, 2 not yet recruiting, 2 terminated. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Not yet recruiting 2, Terminated 2, Completed 1 |
| Phase 3 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Spinogenix: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD) | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 120 | 2026-12-01 | 2026-10-09 |
| Efficacy and Safety of Tazbentetol in ALS Participants Tazbentetol, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 430 | 2026-10-01 | 2026-09-10 |
| Extension Study of Participants From SPG302-ALS-001 SPG302 - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Terminated | Spinogenix | 16 | 2025-05-29 | 2025-12-17 |
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| Study of SPG302 in Adults With Schizophrenia SPG302, Placebo - Schizophrenia | Phase 2 | Active not recruiting | Spinogenix | 32 | 2024-08-01 | 2026-02-06 |
| Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) SPG302, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Spinogenix | 24 | 2024-07-29 | 2025-08-17 |
| Study of SPG601 in Adult Men With Fragile X Syndrome SPG601, Placebo - Fragile X Syndrome | Phase 2 | Completed | Spinogenix | 10 | 2024-07-05 | 2026-05-26 |
| Study of SPG302 in Healthy Volunteers and ALS Participants SPG302, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 | Completed | Spinogenix | 88 | 2023-07-03 | 2025-06-29 |
| Intermediate-size Patient Population Expanded Access Protocol Tazbentetol - ALS (Amyotrophic Lateral Sclerosis) | Available | Spinogenix | 2026-09-25 |
Amyotrophic Lateral Sclerosis (4) · Alzheimer Disease (2) · Fragile X Syndrome (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Dementia (1) · Schizophrenia (1)
Australia (5) · United States (3)
Lauren Priest, MBBS (2) · Brew Brew, MBBS, MD, DSC (1) · Brew Brew, MBBS,MD,DSC (1) · Craig Erickson, MD (1) · David Walling, MD (1) · Dominic Rowe, MD (1) · Ofer M Gonen, MD (1)